# Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft

> **NCT03393273** · PHASE2 · WITHDRAWN · sponsor: **Assistance Publique - Hôpitaux de Paris**

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Elotuzumab

## Key facts

- **NCT ID:** NCT03393273
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-02-20
- **Primary completion:** 2019-01-15
- **Final completion:** 2019-01-15
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Investigator decision in accordance with the promotor
- **Last updated:** 2019-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03393273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03393273, "Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03393273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*